Study Objectives: Below the knee venous thromboembolism (VTE) present difficult decisions for emergency physicians as risks associated with anticoagulation may outweighs the low risk of propagation of clot. Our hypothesis was patients with below the knee deep venous thrombosis (DVT) treated who were compliant with outpatient therapy would have a lower relative risk of propagation and recurrence than noncompliant patients.
Methods: This was a pre-planned secondary analysis of a protocol for low risk outpatient treatment of any VTE using the target specific anticoagulant, rivaroxaban, for outpatient treatment. Inclusion criteria were any patient with an acute isolated below the knee VTE found on duplex doppler ultrasound interpreted via radiologist. Below the knee DVT were defined as posterior tibial, gastroc, and peroneal veins. Compliance was defined as taking medication as prescribed daily for a full 12 weeks, and was done through a series of questions at follow-up. Propagation was defined as any extension of a below the knee DVT to proximal clot (popliteal and above). Recurrence was assessed at 1 yr post treatment through a state wide patient database. Patients who were lost to follow-up were considered non-compliant. Bleeding complications was defined in accordance with ISTH definition of major bleeding. Relative risk was calculated for propagation, recurrence, and bleeding with 95% CI.
Results: 279 patients were diagnosed with DVT and treated with an ODXa inhibitor from 3/25/2013-12/31/2017, of these 67 of these were below the knee DVT. Forty-five patients were compliant with medication therapy. Three patients who were non-compliant developed propagation while no patient on therapy developed propagation. Only one patient had a recurrence of DVT within a year. The relative risk for propagation in compliant patients was 0.07 (95% CI 0.04-1.26) (p¼0.07), with a NNT of 7 to prevent propagation. One non-compliant patient had a reccurence. No patient had a major bleeding event. Four compliant patients had bleeding complications which were: GI bleed (2), bleeding after temporal biopsy (1), bleeding from external hemorrhoids (1). One non-compliant patient had epistaxis and stopped therapy themselves. The relative risk of recurrence (p¼0.25) and bleeding (p¼0.56) did not reach significance.
Conclusions: In this single center study of 66 patients, isolated below the knee DVT had a trend toward a lower risk of propagation to proximal DVT without having any major significant bleeding risk. Teams (PERTs); describing the frequency of team activation, patient characteristics, pulmonary embolism (PE) severity, treatments delivered and outcomes.
Methods: We enrolled all patients from the National PERT Consortium multicenter registry with a PERT activation between October 18, 2016 to October 17, 2017. Data is presented combined and by PERT institutions (with 40 activations). Analyses of PE severity, treatment and outcomes were limited to patients with confirmed PE. 30-day follow-up analyses were limited to subjects for whom follow-up was complete.
Results: In the year of inclusion there were 475 unique PERT activations with acute PE confirmed in 416 (87.6%). The number of activations at each institution ranged from 3 to 13 activations/month/1000 beds with the majority originating from the emergency department (281/475; 59.3%). Figure 1 shows the distribution of patients with confirmed PE according to the European Society of Cardiology risk stratification guidelines. Overall, we found most patients warranting a PERT activation to be at intermediate-low and intermediate-high risk of early mortality. Across institutions, the proportion of patients at low risk ranged from 2.4% to 25.8% while the proportion of highrisk patients ranged from 5.6% to 24.4%. Anticoagulation alone was the most common therapy, delivered to 289/416 (69.5%) of patients with confirmed PE. The overall proportion of patients receiving advanced therapy ranged from 18.7% to 48.6% between institutions. Figure 1 shows the proportions of patients receiving anticoagulation alone versus any advanced therapy stratified by PE risk group. Thirty-day mortality was 15.7% overall, but ranged between institutions from 9.1% to 44.4%.
Conclusions: The frequency of team activation, PE severity, treatments delivered and 30-day mortality varies between 8 US PERTs from the National PERT Consortium TM multicenter registry. Study Objectives: Cerebral oximetry is a portable, non-invasive monitoring system that uses near-infrared spectroscopy (NIRS) to provide continuous, real-time measurements of regional cerebral oxygenation saturation levels (rSo 2 ). We often use other surrogate markers thought to be predictive of severe adverse events such as capnography, pulse oximetry, and supportive airway measures, but the validity of these parameters to accurately reflect vital end-organ oxygenation and procedural risk remain unclear. The primary objective of this study is to evaluate the effect of adult procedural sedation on rSo2 levels. The secondary objective is to assess whether respiratory depression and supportive airway measures occurring during procedural sedation are associated with decreases in rSo2.
EMF
Methods: We performed a prospective observational pilot study on adult patients (>18 years) undergoing procedural sedation in the emergency department (ED). An adhesive sensor was placed unilaterally on the forehead of each patient for rSo2 monitoring. A trained research associate recorded vitals, EtCO2, EtCO2 waveform, SpO2, the level of sedation by the OAAS scale, and rSo2 (CASMED Fore-sight ELITE; Branford, CT) at baseline and then at 1-minute intervals until the patient returned to the baseline level of alertness.
Respiratory depression is defined as: an SpO2 < 92%, a decrease in EtCO2 > 10 mmHg from baseline, or a loss of EtCO2 waveform for > 6 seconds. Supportive airway measures including increased supplemental oxygen, airway adjunct use, repositioning, stimulus for respiration, and assisted ventilation was recorded. An adverse respiratory event (AE) is defined as the occurrence of a supportive airway measure associated with at least one criterion for respiratory depression.
The primary outcome measure is rSo2 values by level of sedation achieved and the incidence of cerebral hypoperfusion during procedural sedation. The secondary outcome is the occurrence of cerebral hypoperfusion during episodes of respiratory AE.
Results: We enrolled 75 subjects [39 female (52%)]. The median (IQR) rSo2 values by each level of sedation achieved on the OAAS scale 1-5, respectively, are 74 (69-80), 74 (70-79), 74 (68-79), 74 (67-81), 72 (68-76). The incidence of cerebral hypoperfusion, as characterized by rSo2 less than 60%, was 9/75 (12%); 2/9 had rSo2 reduction more than 20% from the baseline value; the median (IQR) observed minimum rSo2 in these subjects was 58 (56-59). We observed respiratory depression in 65% (49/75) of subjects with 51% (38/75) requiring supportive airway measures and 39% (29/75) meeting the definition of an AE. During these AEs, 17% (5/29) were associated with cerebral hypoperfusion with a median (IQR) minimum rSo2 of 58 (58-59). Four patients (5%) had cerebral hypoperfusion without a respiratory AE.
Conclusions: Cerebral oximetry monitoring allowed for the identification of subjects experiencing cerebral hypoperfusion during procedural sedation in the ED. Cerebral hypoperfusion is associated with significant morbidity and mortality. Measuring cerebral rSo2 may allow a more accurate measure of procedural sedation risk and patient distress, and a means of measuring some of the physiologic effects of other markers commonly used in procedural sedation. 1) Characterize baseline differences in emergency department (ED) versus inpatient (IP) presenting sepsis patients; 2) Compare ED versus IP presenting sepsis in 2 outcome domains: process outcomes and patient centered outcomes. 3) Estimate risk-differences for patient centered outcomes attributable to disparities in initial resuscitation.
Design: Retrospective consecutive sample cohort. Setting: 9 Tertiary and Community Hospitals in New York over 1.5 years.
Patients: All hospitalized patients with sepsis or septic shock, defined simultaneous 1) Infection AND 2) 2 SIRS criteria AND 3) 1 acute organ dysfunction criterion; with post-hoc confirmation.
Exposure: ED versus IP presenting sepsis. ED sepsis defined as meeting all objective sepsis inclusion criteria while physically in the emergency department. IP sepsis defined as admitted patients meeting criteria after physically leaving the ED.
Outcomes & Analysis: We assessed differences in baseline characteristics for IP versus ED sepsis with a generalized linear model using random effects to account for inter-hospital variability. We then generated a propensity-score for patient "location" when they presented with sepsis, and created a matched (PSM) cohort. We used doubly robust estimation in the PSM cohort to compare outcomes controlling for baseline differences. Process outcomes included 3h-bundle compliance and time to antibiotics. The primary patient outcome was hospital mortality. We calculated attributable risk to determine the proportion of patient outcome differences that were explained by resuscitation differences in groups.
Results: Of 11,182 sepsis hospitalizations, we classified 2,509 (22.4%) as IP and 8,673 (77.6%) as ED. Compared to ED sepsis, IP sepsis patients more often had heart failure (OR: 1.31, 95% CI: 1.18-1.47), renal failure (OR: 1. Conclusions: Sepsis patients in the ED differed dramatically from IP sepsis by demographics, infection source, chronic and acute illness at presentation, and presenting signs. ED patients receive markedly more timely initial resuscitation, and have substantially better outcomes, but this disparity explains only a modest proportion of mortality differences. If and how these 2 populations should be conflated by treatment recommendations is unclear. Study Objectives: Randomized controlled trials (RCTs) provide the most reliable evidence of the impact of medical intervention, however bias can invalidate the results of RCTs. This study aimed to identify the risk of bias of randomized controlled trials (RCTs) referenced in the 2015 American Heart Association (AHA) guidelines update for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC).
Methods: All RCTs cited as references in the 2015 AHA guidelines update for CPR and ECC were extracted. After excluding non-human trials, crossover studies, cluster trials, etc, 2 reviewers assessed the risk of bias among RCTs included in this study. The Cochrane Collaboration's tool for assessing the risk of bias in 6 domains (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting) was used.
Results: A total of 166 RCTs were selected for analyses. Of these, 72.9% (121/ 166) had a high risk of bias for blinding of participants and personnel. Although a small proportion of the trials was at high risk of bias in the remaining 5 domains, 33.7% (56/166) had an unclear risk of bias for random sequence generation, and 45.2% (75/166) had an unclear risk of bias for blinding of outcome assessment. Additionally, among 5 domains of risk of bias excluding random sequence generation, the proportion of trials at unclear or high risk of bias in journals with a relatively high IF (5 and <10) and high IF (10) was lower than that in journals with a low IF (<5)
Conclusions: The proportion of trials at unclear or high risk of bias was high in the 2015 AHA guidelines for CPR and ECC, especially for random sequence generation and blinding of participants/outcome assessment. This tendency was more prominent in journals with a low IF (<5). Risk of bias should be considered when interpreting and applying the CPR guidelines in the clinical setting.
